Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 3/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | GRK2 | P25098 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010002 | 0.83 | QPCT (0.49) | PDE4DPDE4APDE4BPDE4CQPCT | |
| SCHEMBL1009113 | 0.81 | PDE4D (0.45) | PDE4DCYP2C19PDE4APDE4BPDE4C | |
| SCHEMBL1008443 | 0.81 | PDE4D (0.47) | PDE4DALDH1A1CYP1A2CYP3A4TSHR | |
| SCHEMBL1010197 | 0.81 | PDE4D (0.44) | PDE4DPDE4APDE4BPDE4CQPCT | |
| SCHEMBL1009086 | 0.80 | PDE4D (0.43) | PDE4DALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL1010015 | 0.79 | CCR5 (0.45) | PDE4DQPCT | |
| SCHEMBL1008929 | 0.78 | PDE4D (0.44) | PDE4DALDH1A1CYP17A1QPCTKDM4E | |
| SCHEMBL1065950 | 0.77 | CA1 (0.45) | PDE4DALDH1A1TSHRPDE4APDE4B | |
| SCHEMBL1008748 | 0.77 | PDE4D (0.45) | PDE4DALDH1A1LMNAQPCTKDM4E | |
| SCHEMBL1008845 | 0.76 | PDE4D (0.44) | PDE4DALDH1A1PDE4BLMNAQPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268632-B1 | TERTIARY AMINE DERIVATIVES AS PHOSPHODIESTERASE-4 INHIBITORS | CHIESI FARMA SPA (IT) | 2012-08-08 | — | — | EP | claimed |
| EP-2268632-A1 | TERTIARY AMINE DERIVATIVES AS PHOSPHODIESTERASE-4 INHIBITORS | CHIESI FARMACEUTICI S.p.A. (IT) | 2011-01-05 | — | — | EP | claimed |
| US-7820698-B2 | Phosphodiesterase-4 inhibitors belonging to the tertiary amine class | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-10-26 | — | — | US | claimed |
| WO-2009127320-A1 | TERTIARY AMINE DERIVATIVES AS PHOSPHODIESTERASE-4 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-10-22 | — | — | WO | claimed |
| EP-2110375-A1 | Phosphodiesterase-4 inhibitors belonging to the tertiary amine class | CHIESI FARMACEUTICI S.p.A. (IT) | 2009-10-21 | — | — | EP | claimed |
| US-20090258905-A1 | PHOSPHODIESTERASE-4 INHIBITORS BELONGING TO THE TERTIARY AMINE CLASS | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-10-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258905-A1 | PHOSPHODIESTERASE-4 INHIBITORS BELONGING TO THE TERTIARY AMINE CLASS | PDE4A, PDE4B, PDE2A | NR3C1 2156/4885ROCK2 642/4885ROCK1 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.